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Tolerance is a term that has been operationally defined, as 
immunological unresponsiveness to an antigen against which an 
immune response would normally be mounted, and used in this 
manner encompasses a variety of possible mechanisms. One such 
mechanism is carrier-induced tolerance, wrhich in the following 
discussion specifically refers to tolerance induced by hapten 
coupled to isologous serum proteins and is contrasted with 
suppression, which induces tolerance through the mechanism of 
suppressor T cells generated by presenting hapten on cell 
surfaces. 
In this thesis, a new model of suppression is described, 
in which the concept of cell-bound hapten has been extended to 
autoantigens. Nucleosides covalently coupled to spleen cells 
were used to generate suppression of anti-nucleoside antibody 
production. The data to be presented suggest that the mechanism 
involves the induction of T lymphocyte mediated suppression. 
This model is significant in being the first to utilize a 
naturally occurring hapten and is of direct relevance to the 
study of autoimmune disease, specifically systemic lupus 
erythematosus (SLE) a disease whose pathology is caused by the 
production of autoantibody to nucleic acids and resultant 
tissue damage from immune complex deposition (88). One of the 
possibilities proposed for the pathogenesis of SLE is the loss 
of suppressor cells against autoantigen resulting in autoantigen 
production. A model in which suppressor cells can be raised 
against the immune response to the autoantigen, specifically 

2. 
nucleoside, will enable this hypothesis to be tested. Most; ■ 
importantly, the generation of suppression of the antibody 
response to nucleic acids might be of clinical significance in 
the management and treatment of SLE. 
The next section consists of a broad survey of suppressor 
T cells in general followed by a more specific discussion of the 
major hapten-specific suppressor systems in the literature. 
The final section of this introduction is a brief description 
of the rationale and objectives of this thesis project. 

3. 
BACKGROUND OP SUPPRESSOR T CELLS 
Since the concept of suppressor lymphocyte activity was 
first introduced ’oy Gershon in 1970 (1), the suppressor T cell 
(T ) has been demonstrated in the regulation of nearly every 
s 
aspect of the immune response, and has been implicated in a wide 
range of clinical disorders. It is now well documented that 
the suppressor T cell is a distinct subset of T lymphocytes 
characterized by unique, genetically determined cell surface 
antigens (thy 1+ ly 2,3+ I-J+), distinguishing it from the helper 
T cell (thy 1 ly 1 I-J ) and the cytotoxic T cell (thy 1 ly 
2,3+ I-J-) (2-4). Another cell surface marker on the T 
s 
membrane appears to be a histamine receptor (9,10)- Suppressor 
T cells are relatively more immature, functionally short-lived 
and spleen seeking, whereas helper T cells are more mature, 
long-lived and migrate preferentially to the lymph nodes (5,6). 
The mechanism by which the T mediates suppression is 
s 
still controversial although it appears that both antigen- 
specific and non-specific soluble "suppressor factors" are 
elaborated in most suppressor systems studied. The target 
cell of suppressor factor is also controversial with data 
supporting B cells (7), T cells (11) and macrophages (72). The 
best characterization of suppressor factor is by Taussig and 
Holliman who recently produced a suppressor factor specific 
for the antibody response to sheep erythrocytes utilizing the 
technique of a hybrid T-cell line (114). 'This factor is 
specific for SRBC but can also suppress the response to a hapten 
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coupled to the SKBC. The molecule is non-immunoglobulin, 
composed of a large chain and a small chain in non-covalent 
association with a native molecular weight of 200,000 (115)- The 
large chain binds SRBC and the small chain binds H-2 determinants 
(115). 
T cell mediated suppression may be classified into two 
general categories: suppression induced by extrinsic antigen, 
and suppression induced by autologous antigen anti-immunoglobulin 
with specificity for host allotypic and idiotypic determinants 
(7,8). Extrinsically induced suppression may be either antigen 
specific, affecting only the immune responses directed toward 
that antigen, or non-specific, suppressing the immune responses 
to multiple unrelated antigens (8). 
Antigen-specific T cell suppression has been demonstrated 
in a large number of immunologic phenomena: the regulation of 
antibody production e.g. IgC- (11), IgE (12-14), IgM (15), ana 
antibody responses under Ir gene control e.g. nonresponders to 
the terpolymer antigen L-glutamic acid-L-alanine-L-tyrosine 
(GAT) (16, 17, 18). Specific suppression has been demonstrated 
in low zone tolerance (19) and high zone tolerance (20). Anti¬ 
gen specificity has also been found in the suppression of cell- 
mediated immunity. The role of T in blocking the afferent 
s 
and/or efferent limb of contact sensitivity has been extensively 
studied in the picryl chloride (TNCB) system (21,22,23) and 
the dinitrofluorobenzene (DNFB) system (24,25,26). These 
experimental models will be discussed in detail below. Delayed 
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type hypersensitivity induced by sheep erythrocytes (27), murine 
lymphocytic choriomeningitis virus (28), fowl gammaglobulin (29) 
and the hapten asobenzene arsonate (ABA) (30) have all been 
shown to be subject to suppression. The graft versus host 
reaction has been suppressed by Tc in several systems when the 
introduction of immunocompetent cells into histoincompatible and 
immunodeficient hosts is accompanied by an injection of spleen 
cells or thymus cells (31,32). Host responsiveness to various 
murine tumors: methylcholanthrene-induced fibrosarcoma (33), 
Walker lung carcinoma (34,35), mastocytoma (36), ultraviolet- 
induced fibrosarcoma (37) and others (38) are suppressed by 
tumor induced suppressor T cells. 
T cell mediated suppression has been demonstrated to be 
non-antigen specific in a variety of instances. The phenomenon 
of antigenic competition, in which the induction of an immune 
response to one antigen non-specifically interferes with a 
subsequent immune response to second, unrelated antigen (39), 
has been shown to be thymus dependent (40). Antigenic competi¬ 
tion, mediated by T , can suppress antibody responses (6), 
s 
prevent the development of systemic graft versus host reactions 
(5), suppress allograft and tumor rejection (8), and mixed 
lymphocyte reactions (4l), and can also cause acute anergy in 
delayed hypersensitivity (6). Suppressor T cells activated by 
mitogens such as concanavalin A (Con A) are able to suppress 
both cell mediated and humoral responses non-specifically (42-44). 
Once activated, the radiosensensitive precursors of T_ become 
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radioresistant (45). Activation of T requires protein synthesis, 
s 
oxidative phosphorylation and an intact microtubule system (46). 
Non-specific Tg have also been demonstrated in spleen cells of 
neonatal (approximately 14 days) and young mice, and unprimed 
thymus cells (5,6). It has become evident that the development 
and expression of autoimmunity is under the regulation of non¬ 
antigen specific T cell suppression (6,47,48). 
A number of autoimmune disorders have been studied, both 
clinically and in animal and experimental models. The classic 
animal model of autoimmune disease is the New Zealand black 
(NZB) mouse which develops a syndrome of autoimmune hemolytic 
anemia, and glomerulonephritis closely resembling human 
systemic lupus erythematosus (SLE) (49). The Immune system of 
the young NZB mice is mature compared to other strains and is 
characterized by excessive antibody production to some antigens 
and early loss of tolerance to foreign and self antigens (6). 
Adult NZB mice have high titers of thymocytotoxic antibody (6) 
and a markedly reduced population of T lymphocytes resulting 
in unusual viral infections, malignancies, and decreased 
capacity for tumor and graft rejection as well as decreased GVH 
response. In effect, the NZB mouse is characterized by excessive 
B cell function and deficient T cell function. A large body of 
evidence suggests that the loss of suppressor T cell function 
leads to the onset of the autoimmune disease: many of the T 
cell defects are corrected by replenishing the adult NZB mice 
with T cells from young NZB mice (47). Neonatal thymectomy 
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accelerates the course of autoimmune disease (6). Infusion of 
thymosin into young mice delays the appearance of autoantibodies 
(50). Other autoimmune disorders have been studied with similar 
associations between the loss of T and the development of 
s 
autoimmune disease: Hashimoto's thyroiditis (51,52), experimental 
autoimmune encephalomyelitis (53), myasthenia gravis (54), 
experimental autoimmune hemolytic anemia (55), human SLE (56,57) 
and juvenile rheumatoid arthritis (58). 
Whereas autoimmune disorders may in part be due to a 
deficiency of T , there is now evidence that in contrast, 
s 
immunodeficiency disorders may be related to an abnormally high 
number of T ; common variable hypogammaglobulinemia (59), 
selective IgA deficiency (59), "infectious agammaglobulinemia" 
of birds (60). 
The current interest in suppressor cells have resulted in 
many other reports of associations between clinical syndromes 
and diseases, and suppressor cells: aplastic anemia (61), 
fungal infections (62), post-traumatic Immunosuppression (63), 
tropical splenomegaly syndrome (64), melanoma associated immuno¬ 
suppression (65), inflammatory bowel disease (66), sarcoidosis 
(67), diabetes (68), and pregnancy (69). 
Having discussed both specific and non-specific antigen 
dependent T cells mediated suppression, we now turn to T 
s 
suppression of antibody directed against autologous antigen - 
anti-immunoglobulin. These T have specificity for determinants 
s 
on immunoglobulin, both allotypic (70) and idiotypic (71), and 

are generated by the exposure of the animals (neonates) to anti¬ 
immunoglobulin specific for the host allotype or idiotype. That 
cell can suppress idiotype production is advantageous because 
it allows the regulation of immune reactivity to remain even 
after the antigen to which the idiotype was directed, has been 
catabolized and cleared. Idiotype specific T can be induced 
by residual antibody and the host will be able to exert negative 
control on antibody production without the continued presence 
of antigen (7). 
HAPTEN SPECIFIC SUPPRESSOR T CELLS 
Hapten-specific suppression has been investigated exten¬ 
sively in the picryl chloride (trinitrophenyl) system and the 
DNFB (dinitrophenyl) system mentioned above as contact 
sensitivity systems in which the mechanism of tolerance has been 
shown to involve T mediated suppression. These systems, as well 
s 
as several others, will be presented in greater detail and com¬ 
pared with each'other, with regard to the following criteria: 
the hapten, its characteristics and mode of presentation, 
dosage requirement, the kinetics of suppression, specificity, 
transfer suppression and genetic restrictions. 
Hapten coupled cells were first used by Battisto and Bloom 
in 1966 to induce tolerance in guinea pigs to picryl chloride 
(trinitrochlorobenzene) (.31). Intravenous injections were made 
of picryl chloride coupled to syngeneic spleen cells, heat- 
killed spleen cells, erythrocytes and erythrocyte membranes (8l). 
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All forms of membrane-coupled hapten suppressed development of 
delayed hypersensitivity and passive cutaneous anaphylaxis anti¬ 
body formation (81). 
The picryl chloride system was investigated further by 
Asherson and Zembala. 'Their contact sensitivity system consists 
of sensitizing the skin of TNCB mice with picryl chloride and 
challenging 4-5 days later (22). Tolerance is produced by 
multiple i.v. injectionsof picryl sulphonic acid (PSA), a 
soluble form of picryl chloride, and can be transferred by the 
4^ day after sensitization (22). The tolerance is antigen 
specific, T cell dependent, and does not result in decreased 
DNA synthesis or cell proliferation but seems to act on the 
efferent limb of sensitization by inhibiting the expression of 
immune lymph node cells. 
More recently the same investigators have identified 
another suppressor T cell population in the picryl chloride 
system (80). These T are generated by injecting 30 x 10^ 
s 
spleen cells from mice immunized with picryl chloride painting, 
into normal mice which are then immunized 5 days later with 
picryl chloride. The injected T were found to suppress in 
s 
vivo synthesis in the normal mice after 4 days. This T„ 
differs from the T for contact sensitivity induced by the 
o 
injection of picryl sulphonic acid (22) in that it did not affect 
contact sensitivity, its appearance was prevented by cyclophos¬ 
phamide and adult thymectomy had no effect while the reverse was 




Greene, et al have described a different technique of 
eliciting delayed type contact sensitivity reactions in mice in 
the picryl chloride system, that of subcutaneous immunization of 
7 
syngeneic 3 x 10 TNP-modified cell or membranes followed by 
challenging with picryl chloride painted on the skin (82). This 
TNP-induced contact sensitivity response was found to be T cell 
dependent, could be transferred and was subject to suppression 
7 
by 5 x 10 spleen cells from animals which had been tolerised 
g 
with i.v. injection of TNP cell membrane corresponding to 10 
cells (82). The kinetics of suppression showed that i.v. treat¬ 
ment 5 days before subcutaneous sensitization produced maximal 
suppression (82). 
Scott and Long were able to demonstrate B cell tolerance 
7 
in rats that were treated intravenously with 1 x 10 TNP- 
modified spleen cells or lymph nodes as evidenced by decreased 
number of plaque-forming cells to TNP-protein conjugates (83). 
S 6 
Tolerance was achievable with as few as 10 to 10 TNP spleen 
cells, required a latent period of 3-4 days to develop, lasted 
4 weeks, and waned by 6 weeks (83)* Injection of TNP'-modified 
spleen cells also resulted in suppression of hapten delayed 
hypersensitivity (83)- Induction of tolerance required 
cyclophosphamide sensitive T cells and H-2 identity was not 
required (84) as contrasted with the results of Miller, et al. 
(78). 
Ptak and Rozycka found that i.v. injections of TNP bound 
syngeneic erythrocytes or thymocytes tolerized mice to picryl 
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chloride, abrogating contact sensitivity while leaving humoral 
anti-TMP responses intact (85). However, i.v. injections of 
TNP-bound isologous IgG abrogated anti-TMP responses with no 
effect on contact sensitivity to picryl chloride (85). TNP- 
bound macrophages result in suppression of both humoral and 
cell-mediated responses (85). Thus the ”split unresponsive 
state” induced by TNT may be mediated by two separate mechanisms 
which are triggered by different presentation modes. 
The DNFB contact sensitivity system of Claman, Moorhead 
and colleagues is characterized by sensitization of mice with 
direct painting of the DNFB on the skin, and challenge painting 
5 days later, followed by quantitation of contact sensitivity by 
measurement of ear swelling 24 hours later (73)- Tolerance is 
induced 7 days before sensitization by i.v. injection of DMBSO^ 
(a soluble form of DNFB, DNFB bound to either intact cells 
(lymphoid or erythrocytes) or cell ghosts (75)- It was found 
that the stronger the binding between the DNFB and cell membranes, 
the more potent the tolerance (75)- Moreover, intact cells were 
not required, merely membrane bound DNFB (75)* Tolerance could 
be adoptively transferred to normal recipients from tolerant 
donors and this transfer is T cell dependent (76). The 
tolerance induced or transferred is exquisitely specific for 
DNFB (73)- The kinetics of this system are such that the 
induction of tolerance occurs within 24 hours, yet the ability 
to transfer tolerance required a period of 4-7 days to develop 
after i.v. induction and was lost 14 days after which the 
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animal remained tolerant (77)- The authors inferred that there 
are two mechanisms of tolerance to DNFB: 1) a finite period of 
antigen specific suppressor T cell activity which requires 
several days to develop which is responsible for the transfer 
of tolerance and 2) the inhibition of DNFB specific T cell clones 
from receptor blockade by hapten-modified self membranes (77). 
The generation of T In this system has been shorn to be H-2 
s 
restricted (73,79)- Syninduced Tg suppress the efferent limb 
of contact sensitivity by blocking the expression of immune lymph 
node cells (25) and alloinduced T suppress the early afferent 
2 
limb of sensitization by blocking cell proliferation (26). 
5 
Moody, et al found that the i.v. injection of 10 TNP 
coupled syngeneic mouse erythrocytes induced suppression of the 
anti-DNP response to DNP-BGG (87). Minimal suppression 
occurred 7-10 days before Immunization and waned by the 17th day. 
Suppression was found to be T cell dependent and hapten specific 
but not exquisitely so, since TNP-induced suppression depressed 
the response by a DNP immunogen. 
Suppression of delayed hypersensitivity to azobenzene 
arsonate (ABA) in mice has recently been demonstrated (86). The 
7 
suppression was induced by the i.v. injection of 5 x 10 ABA- 
modified spleen cells followed by splenectomy 7 days later and 
transfer of the spleen cells into a recipient that was simultan¬ 
eously immunized subcutaneously with ABA-coupled spleen cells. 
The suppression of DTK was found to be antigen-specific and T 
cell dependent (86). 
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RATIONALE AND OBJECTIVES OF THESIS 
The various models of hapten-specific suppression described 
above have been very useful in elucidating the mechanism of 
suppression, but are all characterized by haptens which are 
irrelevant to the immune response of naturally occurring antigens. 
The model of suppression to be described in this thesis utilizes 
nucleosides as the hapten. Nucleosides, i.e. ribose (or 
deoxyribose) conjugates of the purine (guanine and adenine) 
and pyrrmidine (thymine and cytosine) bases of nucleic acids 
were chosen because previous work by Borel and Stollar (116) 
utilizing nucleoside coupled to isologous protein carriers 
demonstrated nucleoside specific tolerance. The technique 
of coupling determinants larger than nucleosides such as 
oligonucleotides and nucleic acids is currently being perfected, 
and will be applied to the model described here for nucleosides. 
It was thought that by using the techniques of coupling 
nucleosides to protein devised in Borel’s nucleoside 
tolerance model to similarly bind nucleosides to lymphoid cells, 
it might be possible to generate a hapten-specific model of 
suppression for nucleosides analogous to the models reviewed 
above. The results of this thesis show that such a model of 
nucleoside suppression can indeed be generated. 
The objectives of this thesis are: 
(1) to demonstrate that nucleoside-coupled lymphoid ceils can 
induce T cell mediated suppression to anti-nucleoside 
antibody production in vivo and in vitro. 
( 
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(2) to characterize the parameters of this model, namely: 
dosage requirements, kinetics and the specificity of 
nucleoside suppression, 
(3) to assess the role of the cell carrier in the efficacy of 
this suppression and the possibility of an H-2 requirement 
for suppression, 
(4) to ascertain whether there are strain differences in 
suppression and whether or not a strain resistant to 
suppression exists, 
and finally, to determine if suppression to nucleosides 
can be induced in NZB and BWF^ mice. 
(5) 





C57BL/6J, (C57/6J X DBA/2)F^ (hereafter referred to as 
BDF^), DBA/2, BALB/c, SJL/J males were purchased from Jackson 
Laboratories, Bar Harbor, Maine. NZB males were bred from a 
parental stock from the National Institute of Health, Bethesda, 
ID. Animals were fed laboratory chow. All animals entered 
experiments at ages 6 to 8 weeks unless otherwise specified. 
PREPARATION OF IMMUNOGENS AND TOLEROGENS 
HAPTENS 
(Nucleosides) 
Guanosine, adenosine and cytidine were purchased from 
Sigma, St. Louis, Mo. Thymine riboside was purchased from 
Calbiochem, LaJolla, CA. 
PROTEIN CARRIERS 
Keyhole limpet hemocyanin ( KLH ) was obtained from 
Pacific Bio Marine Supply Co., Venice, CA. 
IgG2awas isolated from the serum of plamacytoma-bearing 
BALB/c mice by starch block electrophoresis. 
Nucleosides were conjugated to BALB/c IgG2a (RPC,-) myeloma 
protein as tolerogen or to keyhole limpet hemocyanin as 
immunogen by the procedure of Erlarger and Beiser (89). A 
mixture containing approximately 80 umole of each nucleoside 
was oxidized with 10 ml of 0.1 M sodium periodate and added to 
150 mg of IgG2a (1 umole). After reduction with sodium 
borohydride and extensive dialysis of the product, the conjugate 
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was assayed, for protein by a microbiuret method and for nucleo¬ 
side content by UV spectroscopy. The spectrum was corrected for 
protein content and a millimolar extinction coefficient of 10 
was used as average for the four nucleosides. The immunogen 
preparation was (AGCT)^^_^n^-KLH and G-^-KLH (the subscript 
numbers indicate the total molar ratio of hapten substitution on 
the carrier assuming 800,000 as the molecular weight of KLH). 
Tolerogen preparation was C-^-IgGTa. 
PREPARATION OF CELL SUSPENSIONS 
SPLEEN CELLS (SC) 
Animals were sacrificed by cervical dislocation and the 
spleens were removed and homogenized together in a 15 ml glass 
tissue grinder (Wheaton) in 15 ml of Minimal Eagle's Medium 
(MEM), (Microbiological Associates, Walkersville, MA), washed 
by centrifugation at 1000 RPM for 15 minutes three times in 
50 ml MEM and once in 50 nil of a 50% solution of MEM and 0.15 M 
NaHCO^ at pH 8.0. 'The cells were resuspended in 2 ml of the 
50%0 MEM-NaHCO^ solution and the cell concentration determined in 
a hemocytometer. 
THYMUS CELLS (TC) 
The thymus gland was carefully dissected from each mouse 
and gently teased in MEM. Thymus cells were then washed three 
times in MEM and once in 50 ml of the 50% MEM-HCO^ solution as 
with the spleen cells. 

SHEEP RED BLOOD CELLS (SRBC) 
SRBC's were purchased from Colorado Serum Co., Lab, Denver, 
Colorado and stored at 4°C. Prior to use in hemolytic plaque 
assay or i.v. injection, SRBC's were washed three times in 0.15 M 
NaHCO^.. 
MOUSE RED BLOOD CELLS (MRBC) 
C57BL/6 males were bled under a heat lamp; blood was added 
to an equal volume of Alsever's solution and stored at 4°C. When 
ready for use, MRBC were washed in 0.15 M NaHCCL three times. 
Cells then counted by hemocytometer and appropriate adjustments 
made in concentration. 
HORSE RED BLOOD CELLS (HFBC) 
HRBC's were purchased from Colorado Serum Co. Lab, Denver, 
Colorado, and stored at 4°C. Prior to use, HRBC's were washed 
three times in 0.15 M NaHCO^, counted by hemocytometer and 
adjusted in concentration. 
NUCLEOSIDE MODIFICATION OF LYMPHOID CELLS 
9 
For every 10 cells, 10 mg of guanosine, or 5 mg each of 
guanosine (G), adenosine (A), thymine riboside (T), and cytosine 
(C) for a total of 20 mg of tetranucleoside (AGCT), were used. 
Nucleoside(s) was covalently linked to cells by the method of 
Stollar & Borel (90) but modified to prevent lymphoid cell lysis. 
10 mg of guanosine were suspended in 3 ml of 0.15 M NaKCCL. 
and then oxidized with 1.5 ml of 0.1 M sodium periodate in saline 
for 20 minutes at room temperature. Fne reaction was stopped 
with 15 ul of ethylene glycol which breaks down excess periodate 
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(89). The cell suspension was added dropwise to the oxidized 
nucleoside solution and the mixture was gently stirred at room 
temperature. The binding was stopped after 15 minutes with 100 mg 
t-butylamine borane in 5 ml 0.15 M NaHCCp. After 3 minutes at 
room temperature, the reaction tube (50 ml Falcon) was filled to 
50 ml with MEM and centrifuged for 15 minutes at 1000 RPM. The 
nucleoside-conjugated cells were then washed with MEM 3 more 
times after which appropriate adjustments in cell concentration 
were made. Cells were then ready for intravenous injection via 
tail vein. Sham modified cells were prepared in an identical 
manner except for the addition of 1.5 ml of sodium periodate 
without guanosine. Subsequent treatment with ethylene glycol, 
t-butylamine borane and washings were unchanged. Croups of 5 
mice were used. 
Nucleoside modification of MRBC, SRBC, and HRBC were 
performed by the procedure of Stollar and Borel (90), in 
essentially the same manner as above, except washes were with 
0.15 M NaHCO^ buffer without added MEM, and centrifugations 
were performed at 2000 RPM. 
After the basic system for suppression was established (see 
r 
RESULTS section) with an optimal cell dose of 80 x 10° i.v. on 
day 0 followed by immunization with 0.2 mg nucleoside-KLH in 
Complete Freund's Adjuvant (Difco, Detroit, Mich.) and hemolytic 
plaque assay on day 10, the method for binding nucleoside to 
cells was reevaluated. 
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The method described above is based on the method of 
Erlarger and Beiser used to conjugate ribosides to protein (89). 
The reaction scheme is as follows: 
pH 9-9 5 




(P -purine or pyrimidine; R is H or —P(OH)2) 
The reaction involves oxidizing the ribose ring with periodate 
to give a dialdehyde that couples to free amino groups. ‘The 
resultant bond is stabilized by sodium borohydride, a reducing 
agent. (91) Stollar and Borel modified this procedure for 
linking nucleoside to sheep erythrocytes for use as target cells 
in the hemolytic plaque assay (see below). The modifications 
consisted of the use of 0.15 M bicarbonate to maintain ionic 
strength to prevent lysis and provide a suitable pH for Schiff 
base formation, and the use of t-butylamine borane complex in 
place of sodium borohydride, to prevent membrane damage during 
reduction and to decrease reduction time (90). To bind nucleo¬ 
side to lymphocyte membranes, further modifications were 
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necessary to prevent lymphoid lysis—namely5 to lower the pH 
from 9o to 8.0 by adding an equal volume of MEM at physiological 
pH to the 0.15 M bicarbonate buffer. 
Variations were tried on the above method to attempt to 
evaluate the binding and improve it if possible. In addition to 
the 80 x 10° cells bound to guanosine in the usual manner (MEM 
at pH 8/ t-butylamine borane (Aldrich Chemical Co., Inc., 
Milwaukee, WI) ), Hank’s balanced salts solution (HBSS) (Micro¬ 
biological Associates, Walkersville, MA) was used in place of 
MEM in an attempt to assess the effect of lowering the number 
of free amino groups on binding and reduction by t-butylamine 
borane. Another group consisted of using MEM at physiological 
pH to optimize conditions for cell viability. The original 
reducing agent sodium borohydride was used in place of t- 
butylamine borane in the final group. 
The results shown in Fig. 1. All groups suppressed 
significantly. The three groups exhibiting the most suppression 
were the usual method, HBSS replacing MEM and NaBH^ replacing 
t-butylamine borane. Cell viabilities were 80 to 85$ for all 
groups except for the group using NaBH^ which had 30$ viability. 
Therefore, it appears that viable cells are not required for 
generation of suppression in this system, confirming Claman and 
Miller's results (75)- Since the original method proved to be as 
effective as the variations, no change was made in the basic 




FIG. i The effect of varying conditions for the binding 
of nucleoside on suppression of the immune response to G-KLH. 
30 x 10° syngeneic spleen cells coupled to guanosine by 
5 different conditions of binding, were injected i.v. into 
groups of 5 BDF, mice with a group of untreated mice as 
controls. All mice were immunised on day 5 with 0.2 mg 
G-KLH in CFA i.p. Individual spleen suspensions were 
made from each mouse on day 20 and assayed for PFC 
against C— SRBC targets. Each bar represents the 




INDUCTION OF SUPPRESSION 
Animals were preheated under a heat lamp for vasadilatation. 
Intravenous injections of cell suspensions were made with a 23 
gauge needle via tail vein. 
IMMUNIZATIONS 
0.2 mg of C—KLH or AGCT-KLH in an equal volume of Complete 
Freund's Adjuvant was injected per animal intraperitoneally. (9*0 
IN VITRO CULTURES 
Spleen cell suspensions from either untreated C57BL/6 
mice or C57BL/6 mice injected intravenously with 80 x 10^ 
guanosine-coupled spleen cells 7 days before, were cultured in 
Marbrook-Diener tissue culture conditions in vitro (92). Spleen 
cells were challenged in vitro with guanosine^g-AECM-Ficoll 
(gift of Dr. B. David Stollar) or sheep red cells, or without 
antigen for evaluation of background. Four days later, the 
cells were harvested and assayed by PFC against either G-SRBC 
or SRBC as target. 
HEMOLYTIC PLAQUE ASSAY 
The hemolytic plaque assay of Jeme (93) as modified by 
Stollar and Borel (94) was used to assay the immune response 
to the immunogen nucleoside-coupled KLH. This is measured in 
terms of number of plaque forming cells (PFC) making anti¬ 




Nucleoside-coupled sheep erythrocyte targets were prepared 
by oxidizing nucleoside or tetranucleoside in the same manner as 
described above for binding to lymphocytes. SRBCs were washed 
twice in 0.15 M bicarbonate buffer and 0.5 ml packed cells 
was suspended in 2.0 ml 0.15 M bicarbonate buffer to make a 
20^ suspension. The cells were then added to the oxidized 
nucleosides, binding for 15 minutes at room temperature, reduced 
with 100 mg t-butylamine borane and washed three times with 
0.15 M bicarbonate. 
Animals were sacrificed and individual spleen suspensions 
were made by expressing the tissue through surgical tantalum 
gauze into 5 ml of MEM. 0.05 ml of the nucleoside-coated 
SRBCs and 40 ul of the spleen suspension were added to 1 ml of 
1% Agar (Difco Lab., Detroit, Mich.) in MEM, and the mixture 
was poured In 60 x 15 mm tissue culture dishes (Falcon). The 
plates were incubated at 37° C. for one hour before 1 ml/ plate 
of 1:30 diluted guinea pig complement (Cappel Laboratories, 
Downingtown, PA) was added. The plates were read after an 
additional 45 minutes incubation at 37° C. for direct plaque 
forming cells (PFC). Indirect plaque forming cells were read 
after incubating the plates with 1 ml/plate of 1:200 diluted 
rabbit anti-IgG for an additional hour after reading direct PFC. 
To obtain indirect PFC, direct PFC were subtracted from total 
PFC read after incubating with anti-IgG. No indirect PFCs were 




Statistical analysis was done according to Student's t 
test for significance of difference in PFC numbers between groups. 
The geometric means + standard errors were expressed, p <0.05 






SUPPRESSION BY GUANOSINE-COUPLED SPIEEN CELLS 
Preliminary experiments were done to establish whether 
or not nucleoside-coupled spleen cells could induce suppression 
of the animal's immune response to nucleoside-coupled KLH, a T 
dependent antigen. Guanosine was chosen to be the nucleoside 
in these initial experiments because this nucleoside has been 
shown to be immunodominant in the immune response to all four 
nucleosides of DNA (94). Groups of 5C57BL/6 male mice were 
injected intravenously with varying doses of G-coupled spleen 
cells (G-SC). Control groups consisted of untreated mice or 
mice injected with sham-modified spleen cells. Five days 
later, all animals were immunized with intraperitoneal injections 
of 0.2 mg guanosine-KLH in complete Freund's adjuvant. Direct 
anti-guanosine plaque forming cells were assayed from individual 
spleen suspensions using G-SRBC targets. Suppression of the 
anti-guanosine PFC response was found to be dose-dependent 
6 
(Fig. 2). The optimal dose was 80 x 10u G-coupied spleen cells; 
increasing the dose had no additional effect on suppression. 
80 x 10w sham-modified spleen cells did not suppress the anti-G 
immune response at all. 
KINETICS OF SUPPRESSION 
The time course of suppression was then determined by 
changing the length of time between the i.v. injection of G- 
coupled spleen cells and the i.p. immunizing challenge with 
g 




Fig. 2 The dose response kinetics of suppression of the 
Immune response to guanosine-KLH induced by intravenous 
injection of guanosine-modified spleen cells. Groups 
5 
of five C57B1/6 mice were injected i.v. with 80 x 10 
G-couplea syngeneic spleen cells. Five days later, 
all mice together with a control group of five 
untreated mice, were immunized i.p. with 0.2 mg 
G-KLH in CFA. PFC against G-SRBC targets were 
assayed on day 10. Each point represents the 
geometric mean of PFC per spleen i s.e. of each group 
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spleen cells, the time course of suppression was found to have a 
short: latent period 24 to 48 hours after the i.v. injection, 
to reach a maximum level of suppression when immunization was 
done 5 days after i.v. treatment, and to be completely gone if 
immunization was done 2 weeks later. (Fig. 3)' 
IN VITRO SUPPRESSION 
The short latent period and the transience of suppression 
is characteristic of many other systems (77 - 83, 87), and is 
suggestive that this system like the others, involves T cell 
mediated suppression. To substantiate this, spleen cell 
c 
suspensions from C57BL/6 mice were injected i.v. with 80 x 10 
G-coupled spleen cells, were cultured in vitro 7 days later and 
challenged with a T independent antigen --AECM-Ficoll, with 
SRBC or no antigen. Four days later, the cultures were 
harvested and assayed for direct PFC to guanosine and SRBC. 
The results in Table 1 show that the spleen cells of animals 
treated with G-spleen cells could suppress the B cell response 
to a T independent antigen, G-Ficoll. The suppression is antigen 




Fig. 3 Kinetics of the suppression of the immune 
response to guanosine-KLH. Groups of five C57B1/6 
g 
mice were injected i.v. with 80 x 10 G-coupled 
spleen cells on day 0. Immunization of all mice 
together with a control group of five untreated 
mice, were immunized i.p. with 0.2 mg G-KLH in 
CFA on varying days after i.v. treatment. PFC 
against G-SRBC were assayed five days later. 
Each point represents % suppression of experimental 
group from immune control group. 
WITH G-K LH 
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SPECIFIC SUPPRESSION OF GUANOSINE IMMUNE RESPONSE 
TO A T-INDEPENDENT ANTIGEN IN VITRO 









NONE 550+176 5688+1216 
80 x 10° G-SC i.v. 56+129 -05 5557+1004 
g 
TABLE 1. Spleen cell suspensions from either 80x10 G-SC i.v. 
treated or untreated C57BL/6 mice cultured 7 days later in 
Marbrook-Diener tissue culture conditions and challenged in vitro 
with either Guanosine^o AECM-Picoll or SRBC or without antigen. 
Cultures harvested after 4 days and assayed for PFC against 
G-SRBC or SRBC targets. Each figure represents the mean PFC of 
four cultures + s.s. minus background. PFC background to SRBC 
was 12+63 and background to G-SRBC was 14+99- Statistical 
analysis was done according to Student’s t test. 
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CM TETRANUCLEOSIDE BE SUPPRESSED? 
The tetranucleoside (AGCT) was coupled to spleen cells of 
either C57BL/6 or BDF^ mice and 80 x 10^ or 40 x 10^ AGCT-coupled 
spleen cells were injected i.v. into syngeneic recipients. Five 
days later, these mice together with a control group of untreated 
mice of the same strain, were immunized with tetranucleoside 
coupled to KLH ( AGCT-KLH ). The response to AGCT-KEH was 
assayed by direct PFC to AGCT-SRBC targets. The results (Fig. 4) 
show almost identical suppression by the two strains to both doses 
of AC-CT-SC. 
SPECIFICITY OF SUPPRESSION 
The specificity of the nucleoside tolerance system of Borel 
is exquisite; when the animal is tolerized to guancsine with 
guanosine-IgG2a .and subsequently immunised with AGCT-KLH, an 
antibody response is produced to any nucleoside not conjugated 
to the IgG carrier (90). To assess the specificity of our 
nucleoside suppression systems, groups of five C57BL/6 mice were 
g 
suppressed with 80 x 10 guanosine-SC i.v. and challenged with 
AGCT-KLH on day 5* To ascertain if the animals were responding 
with just anti-G or anti-AGCT or other antibodies, a panel of 
5 differently coupled SRBC targets was provided: AGCT-SRBC, 
A-SRBC, C— SRBC, C-SRBC and T-SRBC, for assay on day 10. For 
comparison, a group was tolerized to C- with G-IgG2a; control 
groups consisted of mice that received 80 x 10° sham-modified 




Fig. 4 Comparative suppression of the immune 
response to AGCT-KLH induced by syngeneic 
AGCT-KLH induced by syngeneic AGCT-Modified spleen 
cells in C57B1/6 and BDF mice. Groups of five 
mice of each strain were treated i.v. with 
f) ft 
30 x 10 arid 40 x 10° syngeneic AGCT-modified 
spleen cells. Lmmunization with AGCT-KLH 
and PFC against AGCT-3RBC targets were 
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32. 
TABLE 2. Groups of C57BL/6 mice were treated i.v. 80 x 10^ 
G-SC. Controls consisted of an untreated group, a group 
g 
receiving 80 x 10 sham-modified SC, and a group made tolerant 
to G with 0.2 mg G-IgG2a. All mice were Immunized i.p. 5 days 
later with 0.2 mg AGCT-KLH in complete Freund's Adjuvant 
Animals were sacrificed on day 10 and individual spleen cell 
suspensions were made and assayed for direct PFC against 
targets coated with 'AGCT as well as targets coated with A, G, 
C, T individually. Values are geometric means of PFC per 
spleen + s.e. 
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The immune response of these G-SC treated animals to SKBC was 
also examined. The results show that treatment with C—SC 
affects not only the immune response to the hapten on the 
modified lymphoid cell i.e. guanosine, but also the immune 
responses to adenosine and cytosine as well. In contrast, 
tolerance induced by G-IgG2a was specific for guanosine. 'Thus, 
the specificity of suppression induced by G-coupled SC is 
broader than the tolerance induced by G-IgC-2a. The suppression 
was specific for nucleosides, however, as the immune response 
to SRBC, an unrelated antigen, was unaffected in vivo. (PFC 
to SRBC = 158,700 - 30,200 in G-SC treated mice five days before 
challenging with 0.1 ml of 20% SRBC suspension, and PFC = 
158,600 - 21,500 in ’untreated mice similarly challenged.) 
ROLE OF 'THE CELL CARRIER 
Thus far in our system, the spleen cell seems to be a very 
effective cellular carrier for hapten-specific tolerance. The 
next experiment varied the cell carrier in an effort to discover 
whether any other cell type might serve as an optimal carrier 
for nucleosides. The results are shown in Fig. 5- Syngeneic 
splenocytes 'were the most effective carriers for suppression; 
thymus cells induced significant suppression but only half as 
well as splenocytes. Syngeneic and xenogeneic erythrocytes 
were ineffective carriers of nucleoside suppression. 


FIG. 5 The role of the cell carrier in suppression of 
the immune response to AGCT-KLH. 80 x 10 cells of 
different types were coupled to AGCT and injected i.v. 
into groups of 5 C573L/6 mice. All mice together with 
a control group of untreated mice were immunised 5 days 
later with 0.2 mg AGCT-KLH in CFA i.p. PFC against 
AGCT-SRBC targets were assayed on day 10. Each bar 












































STRAIN DIFFERENCES IN NUCLEOSIDE SUPPRESSION 
All the data presented have been in the C57BL/6 and the 
BDFn strains. Interestingly, the comparative data between 
the parent and the F^ with regard to AGCT-airected suppression 
were very similar. (Fig. 4) The next question asked concerned 
whether there existed any strain differences in the generation 
of suppression and whether there existed any strains which 
were resistant to suppression with nucleosides. 'The DBA/2 
(the other parental strain of the BDF^), the SJL/J and the 
BALB/c were tested, using the dose of 80 x 10° spleen cells 
coupled to AGCT and administered i.v. into syngeneic recipients. 
The results are presented in Fig. 6. All strains could be 
suppressed except for the SJL/J which did not exhibit 
significant suppression. 
The final experiment to be presented represents the 
natural endpoint for the techniques generated by this system— 
namely, the investigation of T cell suppression'in the New 
Zealand mice: the New Zealand Black (NZB), the New Zealand 
White (NZW) and the (NZB X NZW)F^ or the BWF^. This system 
would enable the investigation of the current notion that 
the pathogenesis of autoimmunity in the NZB/W mice is due to 
loss of suppressor cell activity with age allowing forbidden 





FIG. 6 Strain differences in the suppression of the 
immune response to AGCT-KLH3 induced by syngeneic AC-CT- 
couplea spleen cells. ^ represents immune controls, i 
represents suppressed response. 80 x 10° AGCT-coupled 
syngeneic spleen cells were injected i.v. into groups 
of five mice. Five days later, all mice were immunized 
with 0.2 mg AGCT-XLH in CFA i.p. PFC against AGCT- 
SR5C targets we re assayed on day 10. Each bar represents 






















Relatively young (8-12 weeks) male NZB mice and 6 week 
old male BWF, mice were injected i.v. with 80 x 10^ AGCT-coupled 
syngeneic spleen cells and immunized on day 5 with 0.2 mg 
AGCT-KLH per usual. The result is shown in Fig. 7- A high 




. 7 The suppression of the immune response 
AGCT-KLH induced by syngeneic AGCT-coupled 
een cells in 8 to 10 week old MZE male mice 
5 week old BWF, male mice. 
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Suppression induced by a variety of haptens presented on 
cells has been extensively investigated as reviewed above. In 
this thesis is presented a new model of suppression directed 
against the immune response to nucleosides, naturally occurring 
haptens which are components of nucleic acids. Suppression to 
nucleosides is cell dose dependent, requires a latent period 
to develop and has transient kinetics. Suppression was induced 
against both a T dependent antigen in vivo and a T independent 
antigen in vitro; this together with the kinetic profile is 
strongly suggestive of T cell mediated suppression. Anti¬ 
nucleoside suppression is antigen-specific but lacks the 
exquisite specificity of carrier-induced tolerance. Except 
for SJL/J mice, anti-nucleoside suppression was demonstrated 
in all strains of mice tested including the NZB and BWF- mice. 
Preliminary data show that the spleen cell is the most effective 
cell carrier for suppression and suggests that there is an 
H-2 requirement for anti-nucleoside suppression. 
In this model of anti-nucleoside suppression, nucleosides 
are coupled directly to cells by covalent bonding to membrane 
proteins. This coupling is stable after reduction. There 
is no secondary binding of the nucleoside in vivo once this 
coupling has occurred. Whether the resultant nucleoside- 
membrane complex is catabolized and/or pinocytosed is not 
known. 
After covalent conjugation, the nucleoside-modified cells 
were injected intravenously into syngeneic mice. A humoral 

40. 
immune response was then Induced by the intraperitoneal immuniza¬ 
tion of nucleoside conjugated KLH. Suppression of the anti- 
nucleoside response was assayed by hemolytic plaques 5 days 
after immunization. Significant suppression was observed for 
both guanosine and for the tetranucleoside AGCT. The optimal 
conditions for suppression with nucleoside-coupled spleen cells 
g 
was found to be a dose of SO x 10 nucleoside conjugated spleen 
cells injected i.v. 5 days prior to immunization. The kinetics 
of suppression showed that the phenomenon is transient, requiring 
a latent period of 24-48 hours, reaching a peak after 5 days 
and disappearing by 2 weeks. 
The transience of this anti-nucleoside suppression is 
similar to the transience found in other systems of suppression 
shown to be mediated by suppressor T cells (77,82,83,87,95)- 
The latent period and transient kinetics of these systems 
presumably represent the Induction and differentiation of 
suppressor T cells, an active process requiring DNA synthesis. 
Indeed, Miller, et al. (77) and Scott (84) found that the 
suppressor mechanism in their system was cyclophosphamide 
sensitive. These kinetics are hypothesized by Naehtigal, et al. 
(99) as being due to the short functional life span (approximately 
14 days) of immature suppressor cell precursors. Their model 
describes the immature T as either dying within 2 weeks or 
s 
differentiating into a mature stage after which differentiation 
into suppressor cells was no longer possible (10). This model 
was based on experiments in which adult thymectomised mice 
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were able to be tolerized and produce specific T , only up 
s 
until 14 days after thymectomy. After 14 days, the mice were 
unable to produce T presumably because the pool of thymic T 
s s 
precursors was exhausted (10). 
Suppression was induced to the immune response against 
both a T dependent antigen (KLH) in vivo and to a T independent 
antigen (Ficoll) in vitro. This, together with the kinetic 
profile of nucleoside suppression is consistent with a suppressor 
T cell system. Furthermore, much work on the mode or route 
of administration of haptenated cells by Benacerraf, et al. and 
others, (82,86) has established that intravenous administration 
preferentially stimulates suppressor responses. While the 
same cell preparation adminsterea subcutaneously results in 
delayed type hypersensitivity (82,86), the simultaneous adminis¬ 
tration of cells by both routes preferentially generates 
suppressor T cell responses and suppress the development of 
contact sensitivity (82). The reason for this phenomenon 
might be the lymphoid tissues the injected cells first encounter: 
intravenously injected cells tend to localize in the spleen 
while subcutaneously injected cells localize in lymph nodes (86). 
Rich, et al. (103) found that after sensitization, spleen cells 
suppressed MLR responses while lymph node cells enhance MLH. 
Sy, et al. (100) demonstrated a splenic requirement for 
induction of suppressor T cells: splenectomy before administra¬ 
tion of DNFB did not result in T . The spleen was found to be 
s 
required at least 3 days after tolerization. 
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The results presented in this thesis are suggestive of 
T involvement but do not definitely prove it. Conclusive 
s 
proof showing abrogation of suppression with treatment with 
anti thy 1-2 and complement in vitro as well as demonstration 
of nylon wool enrichment of suppression, are currently in 
progress. Other experiments planned to further substantiate 
suppressor T cell involvement include adoptive transfer of 
splenocytes from mice suppressed with 80 x 10^ AGCT-SC 5-7 days 
prior to transfer, as well as in vitro studies of the effects 
of culture supernatants or cell-free extracts on suppression. 
Hopefully, these data will further elucidate the cellular and 
biochemical mechanisms of this system. 
From the results presented above, it appears that there 
now exists 2 different techniques for inducing immunological 
unresponsiveness to nucleosides, the carrier-induced toleranced 
mechanism described by Borel and Stollar (116) using nucleoside 
coupled to isologous gammaglobulin and the suppression induced 
by nucleoside coupled to syngeneic lymphoid cells. The 
mechanisms of "tolerance" and "suppression" are presumably 
different. Presenting hapten on soluble protein carriers 
results in tolerance through receptor blockade of B cells (117). 
This model postulates that B cells are rendered unresponsive 
i.e. tolerant, when their antigen receptors are reversibly 
occupied by the hapten-carrier conjugate (97). Presenting 
hapten on cell surfaces results in the generation of a clone 
of antigen-specific suppressor T cells (75,78,79,86). The 
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precise mechanism of this process is not known. A possible 
explanation may be that the T receptor recognize larger 
s 
determinants e.g. membrane bound hapten, as opposed to the smaller 
complex of protein-coupled hapten recognized by B cells. It 
is well established that antigen cross-reactivity at the T cell 
level is broader than at the antibody level (llS). This 
difference in cross-reactivity between the T cell receptor and 
the B cell receptor could account for the exquisite specificity 
of B cell anti-nucleoside tolerance and the somewhat broader 
specificity observed for presumed anti-nucleoside T cell 
suppression. 
The mechanism of T cell mediated suppression in the DNFB 
and the picryl chloride (TNCB) contact sensitivity systems has 
been extensively investigated and it is now known that can 
inhibit either the early cell proliferative phase of contact 
sensitivity (the afferent limb of sensitization) or inhibit 
the expression of immune effector cells (the efferent limb of 
sensitization). It is of interest that different haptens / 
antigens induce that inhibit different limbs of sensitization. 
Cell proliferation has been shown to be the target of T in the 
O 
suppression of DNFB contact sensitivity (26,119), suppression 
of MLC responses (120,121), and responses to type III pneumo¬ 
coccal polysaccharide (122). Inhibition of the efferent limb 
or expression of an immune response has been demonstrated for 
picryl chloride contact sensitivity (22), DNFB contact sensitivity 
(25) and response to tumor antigens (123). It is interesting 
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that the difference of one nitro group (DNFBvs picryl chloride) 
results in a comolete alteration of the mechanism of T 
s 
suppression. 
Miller, et al. have recently shorn in the DNFB contact 
sensitivity system, that the suppressor T cells induced by 
syngeneic DNP-coupled lymphoid cells (syninduced T ) selectively 
s 
block the efferent limb of sensitivity by inhibiting the expres¬ 
sion of lymph node cells from sensitized animals (25). Co¬ 
transferred syninduced Tg block the passive transfer of contact 
sensitivity to normal recipients. Syninduced T„ did not affect 
the afferent limb of sensitization and are not H-2 restricted. 
In contrast. Miller, et al. found that the afferent limb was 
selectively inhibited by T induced by allogeneic DNP-coupled 
2 
lymphoid cells (alloinduced T ) leaving the efferent limb 
•D 
unaffected (26). The target of alloinduced T appears to be 
s 
cell proliferation as measured by DNA synthesis. Recipients 
of alloinduced T fail to generate immune lymph node cells 
O 
capable of transferring contact sensitivity to normal animals. 
The suppression by alloinduced T appears to be H-2 restricted. 
s 
It is possible that the roles of afferent and efferent blockade 
in suppressor cell regulation are different: afferent blockade 
may serve to maintain self-tolerance while efferent blockade 
may serve to limit clonal expansion after normal immune 
responses have gotten under way (26). The mechanism of our 
model of anti-nucleoside suppression has not been dissected 
sufficiently to determine the precise site of T„ action. 
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The mechanism of action of suppressor T cells has been 
found to be mediated by soluble factors in many systems of 
suppression. Tada et al. (11) characterized an antigen-specific 
suppressor factor from mice immunized with KLH as smaller than 
immunoglobulin and containing antigens coded for by the I-J 
region of the major histocompatability complex (MHC). Kapp and 
Benacerraf (123) isolated a very similar soluble factor from 
nonresponder mice primed with GAT which differed in being less 
MHC restricted in action. Asherson and Zembala (22) described 
a suppressor factor specific for the picryl chloride contact 
sensitivity system. It bears H-2 determinants and is selective 
for the efferent limb of contact sensitivity. The soluble 
factor isolated for the DNFB contact sensitivity system is 
also selective for the efferent limb and is H-2 restricted 
(24,125)* The most recently characterized antigen-specific 
suppressor factor by Taussig, et al. (114) was described in the 
introduction of this thesis. A number of non-antigen specific 
factors have also been well characterized. Pierce and Kapp 
isolated a soluble immune response suppressor (SIRS) from CcnA- 
inauced T cells which suppress PFC responses non-specifically 
(6). It does not contain antigens coded by by MHC and has 
many biochemical similarities to MIF. Rich and Rich isolated 
a non-specific suppressor factor secreted dining mixed lympho¬ 
cyte reaction (126). Tnis factor bears MHC antigens coded for 
by the I-C region, and is MHC restricted in action. 
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The isolation of nucleoside-specific suppressor factor from 
the anti-nucleoside suppression model would be useful in several 
ways. It would first substantiate the involvement of Tg cells in 
the system. It would also allow us to test whether or not suppres¬ 
sion of anti-nucleoside antibody can be suppressed without the use 
of cell bound hapten in vivo. The outcome of this experiment 
could be significance for new modes of therapy In systemic lupus 
and other disorders thought to involve T cell suppression. 
The syngeneic splenocyte was found to be the most effective 
carrier for suppression of anti-nucleoside. This is consistent 
with other models of suppression (77,82,83) confirming the potency 
of hapten-coupled lymphoid cells as ”tolerogenM. AGCT-thymocytes 
suppressed significantly also, Syngeneic erythrocytes and 
xenogeneic (horse) erythrocytes did not suppress significantly 
from the control response, The results suggest that the presence 
of H-2 antigen might be required on the carrier cell surface in 
order for suppressor T cells to be generated: thymocytes have 
approximately one fourth the amount of H-2 antigens on spleen 
cells, and erythrocytes have virtually no H-2 antigen on the 
membrane (104), This H-2 requirement is consistent with the H-2 
requirement well-established for T cell mediated cytotoxicity (105,106) 
and for some but not all systems of T cell mediated suppression 
(78,79,84). Further experiments using H-2 incompatible spleen 
cell from allogeneic strains or H-2 negative cells from tumor 
cell lines e.g, teratoma cell lines as carriers will be needed to 
substantiate the H-2 requirement. 
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The interesting point to consider here is that while no 
suppression was generated in the nucleoside system by haptenated 
syngeneic erythrocytes, suppression was evident in other systems 
(81,87,95,107,108). The hapten used in these other systems was 
either TNP or DNP and it is possible that the cell surface bound 
with nucleoside is less tolerogenic than when bound with these 
compounds. An alternative explanation might simply be that the 
nucleoside system is hT-2 restricted whereas the other systems 
are not. Further experiments are in progress to examine the 
effectiveness of administering nucleoside-coupled macrophages, 
lymph node cells, bone marrow cells, and purified B and T cells. 
Long and Scott (83) found that thymocytes were "marginally 
effectiveM in tolerogenecity, and B cells and bone marrow cell 
were ineffective. 
Using the data for optimal suppression in the C57BL/6 and 
BDF^ strains, i.e. 80 x 10^ ACtCT-SC i.v. followed by immunization 
on day 5, several inbred strains were examined for capacity to 
generate suppression. All the strains examined: C57BL/6J, 
DBA/2, BDF^, (C57BL/6J x DBA/2)F1, BALB/C could generate 
suppression except for SJL/J, which did not have significant 
suppression. It is interesting that SJL are high responders 
to nucleoside antigens (110) and fail to suppress, while BALB/C 
are low responders and suppress very well C109). It is possible 
that SJL lack a T clone for regulating the response to nucleic 
s 
acids, hence decreasing the capacity to generate suppression. 
There may be other host factors peculiar to SJL involved. SJL 
mice were recently found to have age-dependent loss of suppressor 
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ability (111). An interesting study will be to attempt to 
generate T in SJL with AGCT-BALB/C SC, to do the same in BALB/C 
with AGCT-SJL SC, and to raise suppression in the (BALB/C X SJL/J) 
F^ with AGCT-coupled to parental strain SC. 
Two findings of this research project are of direct relevance 
to SLE: 1) the successful generation of suppression in young NZB 
male mice and BWF, male mice and 2) the specificity of suppression 
induced by G-SC is broader than the specificity of tolerance 
induced by G-IgG. 
The age dependent loss of suppressor T cell in NZB and NZB/ 
NZW F^ (BWF^) mice has been reported occurring between 1 and 2 
months of age, according to thymocyte proliferation and antigen- 
induced suppression assays (112). It is thus very important that 
suppression was successfully generated in these 8-12 week old mice 
showing that there is no genetic inability of NZB and BWF,, mice to 
generate T^ to nucleosides. Possessing a system of suppression 
directed against an antibody thought to be the cause of tissue 
damage in SLE will allow us to test the hypothesis that the 
pathogenesis of SLE is due to the loss of suppressor T cells. 
Experiments on the NZW and BWF, are in progress and can reveal 
relevant information on the possible genetic defects in suppression. 
Sex differences in the generation of suppression will also be 
examined. If suppressor cells can be successfully generated, it 
will be important to assess the resultant effect on anti-DNA 
production as well as the ensuing clinical course of murine lupus. 
The finding that the specificity of T cell suppression is 
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broader than B cell mediated tolerance has obvious therapeutic 
implications for murine lupus. If oligonucleotides could be 
coupled to lymphocytes, the resultant suppression could have 
specificity broad enough to include not just anti-oligonucleotide 
but antibodies to all nucleic acids including native DMA and RNA. 
The broad amplications of the nucleoside suppression model 
in the NZ mice are enormous and will hopefully reveal not only 
possible therapeutic regimens for human SLE, but elucidate basic 
cellular mechanisms of Immunologic regulation and tolerance. 
The basic system of inducing suppression to nucleoside 
antigens gives us a tool to explore many new areas and 
happily generates more questions than answers. Can an ongoing 
immune response to nucleosides be suppressed? Can a secondary 
response to nucleosides be suppressed? Can cell mediated immunity 
i.e. cytotoxic ,Tkiller’T cells or delayed hypersensitivity to 
nucleoside antigens be generated? What is the effect of suppression 
induction on the production of anti-DMA? What is the role of 
the major histocompatability complex in autoimmune disease? 
Hopefully, the answers to these questions and the Important 
questions related to SLE can be found using the techniques generated 





A new model of suppression is presented in which suppressor 
cells to autoantigens i.e. nucleosides have been generated in 
vivo and in vitro in mice. This was done by covalent coupling 
of the four nucleosides of DNA to lymphoid cells. The 
following observations were made: 
1) The suppression is dose dependent, requires a latent 
period to develop and is transient. 
2) Anti-nucleoside antibody forming cells to both T 
dependent and T independent antigens were suppressed. 
3) The suppression is antigen-specific but the 
specificity of suppression (induced by nucleoside- 
coupled cells) is broader than the specificity of 
tolerance (induced by nucleoside-coupled gammaglobulin). 
4) Anti-nucleoside suppression appears to require H-2 
antigen on the cell carrier. 
5) Suppression of anti-nucleoside antibody can be 
generated in a variety of strains of mice except for 
the SJL/J strain. 
6) NZB and BWF, mice have the ability to generate 
suppression to anti-nucleoside antibody, 
This model of suppression is significant for the study of 
systemic lupus because 1) it will allow us to test the hypothesis 
that the pathogenesis of this disorder is due to the loss of 
suppressor cells, and 2) the ability to generate nucleoside- 
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